Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
UNIVERSITE DE MONTPELLIER has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 5 distinct examiners and 5 distinct art units, showing that the current docket spans separate examination assignments rather than a single concentrated path.
CHRISTIANSON, SKYLAR LINDSEY is the busiest examiner, with 1 pending matter. Because no examiner or art unit accounts for more than that identified amount, prosecution management should emphasize matter-by-matter review, with claim strategy and technical explanations tailored to each assignment.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHRISTIANSON, SKYLAR LINDSEY | 1 | 60.9% | +25.4% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
| LAFAVE, ELIZABETH ROSE | 1 | 64.4% | +43.2% |
| PENNINGTON, KATIE LEIGH | 1 | 31.8% | +58.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17756456 | MESENCHYMAL STEM CELLS WITH ENHANCED THERAPEUTIC PROPERTIES | PENNINGTON, KATIE LEIGH | 15d |
| 18546300 | COMBINATION OF A SERCA2 INHIBITOR AND A STING ACTIVATOR FOR USE IN TREATING AND/OR PREVENTING CANCER | DEKARSKE, MADELINE MCGUIRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275331 | BILE SALTS BACTOSENSOR AND USE THEREOF FOR DIAGNOSITC AND THERAPEUTIC PURPOSES | ARMATO JR, DENNIS IGNATIUS | 30d overdue |
| 18041902 | EUKARYOTIC DNA REPLICATION ORIGINS, AND VECTOR CONTAINING THE SAME | LAFAVE, ELIZABETH ROSE | 6d |
| 17756456 | MESENCHYMAL STEM CELLS WITH ENHANCED THERAPEUTIC PROPERTIES | PENNINGTON, KATIE LEIGH | 15d |
| 18293096 | INTERLEAVED NEURAL STIMULATION | CHRISTIANSON, SKYLAR LINDSEY | — |
| 18546300 | COMBINATION OF A SERCA2 INHIBITOR AND A STING ACTIVATOR FOR USE IN TREATING AND/OR PREVENTING CANCER | DEKARSKE, MADELINE MCGUIRE | — |
| Art Unit | Apps |
|---|---|
| 3792 | 1 |
| 1622 | 1 |
| 1651 | 1 |
| 1684 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18293096 | INTERLEAVED NEURAL STIMULATION | CHRISTIANSON, SKYLAR LINDSEY | 3792 | §103 | Final Rejection | — | Pending | Jan 29, 2024 |
| 18546300 | COMBINATION OF A SERCA2 INHIBITOR AND A STING ACTIVATOR FOR USE IN TREATING AND/OR PREVENTING CANCER | DEKARSKE, MADELINE MCGUIRE | 1622 | §102§103 | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18275331 | BILE SALTS BACTOSENSOR AND USE THEREOF FOR DIAGNOSITC AND THERAPEUTIC PURPOSES | ARMATO JR, DENNIS IGNATIUS | 1651 | §103 | Final Rejection | 30d overdue | Pending | Aug 01, 2023 |
| 18041902 | EUKARYOTIC DNA REPLICATION ORIGINS, AND VECTOR CONTAINING THE SAME | LAFAVE, ELIZABETH ROSE | 1684 | §103 | Non-Final OA | 6d | Pending | Feb 16, 2023 |
| 17756456 | MESENCHYMAL STEM CELLS WITH ENHANCED THERAPEUTIC PROPERTIES | PENNINGTON, KATIE LEIGH | 1634 | §102§103 | Non-Final OA | 15d | Pending | May 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE DE MONTPELLIER has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Skylar Lindsey Christianson has the most, with 1 of UNIVERSITE DE MONTPELLIER's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
